Technical Analysis for SVRA - Savara, Inc.

Grade Last Price % Change Price Change
grade F 0.93 1.10% 0.01
SVRA closed up 1.1 percent on Wednesday, October 16, 2019, on 67 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Up
See historical SVRA trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Narrow Range Bar Range Contraction 1.10%
Wide Bands Range Expansion 1.10%
Oversold Stochastic Weakness 1.10%
Narrow Range Bar Range Contraction 7.24%
NR7 Range Contraction 7.24%
NR7-2 Range Contraction 7.24%
Wide Bands Range Expansion 7.24%

Older signals for SVRA ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.
Medicine Medical Specialties Pharmaceutical Cystic Fibrosis Heart Failure Heart Diseases Staphylococcus Aureus Treatment Of Heart Failure Total Synthesis
Is SVRA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 11.96
52 Week Low 0.82
Average Volume 413,683
200-Day Moving Average 5.9589
50-Day Moving Average 2.1212
20-Day Moving Average 1.7391
10-Day Moving Average 0.9097
Average True Range 0.1848
ADX 39.71
+DI 14.6604
-DI 42.9135
Chandelier Exit (Long, 3 ATRs ) 2.6756
Chandelier Exit (Short, 3 ATRs ) 1.3744
Upper Bollinger Band 3.5763
Lower Bollinger Band -0.0981
Percent B (%b) 0.28
BandWidth 211.281697
MACD Line -0.4528
MACD Signal Line -0.3806
MACD Histogram -0.0722
Fundamentals Value
Market Cap 22.51 Million
Num Shares 24.2 Million
EPS -3.50
Price-to-Earnings (P/E) Ratio -0.27
Price-to-Sales 526.42
Price-to-Book 2.64
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.03
Resistance 3 (R3) 1.03 1.00 1.01
Resistance 2 (R2) 1.00 0.97 1.00 1.01
Resistance 1 (R1) 0.96 0.96 0.98 0.96 1.00
Pivot Point 0.93 0.93 0.94 0.93 0.93
Support 1 (S1) 0.90 0.91 0.92 0.90 0.86
Support 2 (S2) 0.87 0.89 0.87 0.85
Support 3 (S3) 0.83 0.87 0.85
Support 4 (S4) 0.83